51 F
New York
Saturday, April 10, 2021

Teva [NYSE: TEVA] Gets EU Authorization for Seffalair and BroPair Spiromax

Must read

Cameco [NYSE: CCJ] Plans to Restart Cigar Lake Uranium Mine

Cameco Corporation declared that it has decided to resume the cigar lake uranium mine. The firm is intending to restart production in the...

Lucira [NASDAQ: LHDX] COVID-19 Test Kit Reactive to 99.9% of COVID-19 Strains

Lucira Health, Inc. shares skyrocketed more than 18% during the pre-market trading session of Friday after the firm disclosed that its all-in-one COVID-19...

Johnson Control [NYSE: JCI] Buys Silent-Aire

Johnson Controls International Plc disclosed Friday that it has bought Silent-Aire. The deal has valued Silent-Aire at up to $870 million. It also...

Teva [NYSE: TEVA] Gets EU Authorization for Seffalair and BroPair Spiromax

Teva Pharmaceutical Industries Limited disclosed that it has got EU Marketing Authorization for Seffalair Spiromax and its duplicate BroPair Spiromax. This is the...

Teva Pharmaceutical Industries Limited [NYSE: TEVA] disclosed that it has got EU Marketing Authorization for Seffalair Spiromax and its duplicate BroPair Spiromax. This is the greatest accomplishment for the firm. It will deliver new cure options to healthcare experts who aid people living with conditions such as asthma.

Furthermore, the firm has committted to empower the victims who has been living with asthma to mange their condition. At the same time, it also provide cost-effective cure to healthcare systems.

Launch of Seffalair and BroPair Spiromax

Teva Pharmaceutical disclosed that it has scheduled the rollout in Spain, Portugal, UK, and Switzerland. Since the rollout of DuoResp Spiromax, the Spiromax inhaler has been well supported by healthcare experts and sufferers. Additionally, Inhaler technique and therapy devotion are important factors in enhancing results for asthma sufferers.

About Seffalair and BroPair Spiromax

Seffalair Spiromax and BroPair Spiromax are designated as a routine therapy for asthma in grown-ups and youngsters at the age of 12 years and older not appropriately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonists.

More articles

Latest article

Amyris [NASDAQ: AMRS] Declares Pricing of Public Offering of Common Stock

Amyris, Inc.  declared that it has commenced the proposed underwritten public offering of shares of its common stock. It has disclosed that is...

Nokia [NYSE: NOK] Roll Out Innovative Cloud Charging Solution on AWS for CSPs

Nokia Corporation has rolled out a cloud-native convergent charging solution on Amazon Web Services (AWS) to speed up communications service providers (CSPs) migration...

Niu Technologies [NASDAQ: NIU] Shares Q1 E-Scooter Sales Volume Results

Niu Technologies has reported the e-scooter sales volume-outcome for the Q1 2021 and update on new products unveiling. The firm disclosed that the...

GameStop [NYSE: GME] is Plunging Today. Here’s Why

Shares of GameStop Corp. is plunging during the pre-market trading session of Monday. The firm’s shares tumbled -16.08% as it lost -30.80 during...

Ceragon [NASDAQ: CRNT] Chosen by TIM Brazil to Take Part in TIP 5G OpenRAN Trials

Ceragon Networks Ltd. disclosed that TIM Brazil has chosen the firm to take part in TIP OpenRAN Trials. After the selection, CRNT will...

Alphabet’s [NASDAQ: GOOGL] Waymo CEO Resign from His Position

Alphabet Inc. has disclosed that the CEO of its subsidiary Waymo has resigned from his position as the CEO of the self-driving startup....

Tesla [NASDAQ: TSLA] Announces First Quarter Vehicle Production & Deliveries Results

Tesla Inc. has reported Friday the details of vehicles it has produced and delivered during the first quarter of 2021. The firm has...

XPeng [NYSE: XPEV] Reports March and First Quarter 2021 Vehicle Delivery Result

XPeng Inc. has disclosed the vehicle delivery results for the month of March and the first quarter of 2021. XPEV revealed that it...